TuisPSTV • NASDAQ
add
Plus Therapeutics Inc
Vorige sluiting
$0,26
Dagwisseling
$0,25 - $0,26
Jaarwisseling
$0,16 - $2,08
Markkapitalisasie
43,00 m USD
Gemiddelde volume
5,60 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 1,37 m | -3,19% |
Bedryfskoste | 4,17 m | 33,33% |
Netto inkomste | -5,71 m | -46,37% |
Netto winsgrens | -417,92 | -51,19% |
Wins per aandeel | 0,00 | 100,00% |
EBITDA | -5,60 m | -57,57% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 8,61 m | 138,82% |
Totale bates | 16,32 m | 146,12% |
Totale aanspreeklikheid | 12,33 m | -20,88% |
Totale ekwiteit | 4,00 m | — |
Uitstaande aandele | 171,55 m | — |
Prys om te bespreek | 8,69 | — |
Opbrengs op bates | -82,04% | — |
Opbrengs op kapitaal | -176,22% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -5,71 m | -46,37% |
Kontant van bedrywe | -6,26 m | -416,68% |
Kontant van beleggings | -1,08 m | -1 782,81% |
Kontant van finansiering | 2,80 m | — |
Netto kontantverandering | -4,53 m | -295,03% |
Beskikbare kontantvloei | -4,01 m | -1 221,55% |
Meer oor
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecular diagnostic service, CNSide®. Wikipedia
Gestig
1996
Hoofkwartier
Webwerf
Werknemers
21
